BMPR2 and pulmonary arterial hypertension: In addition, it is often considered genetically associated due to the inactivating mutation of a gene named Bone morphogenetic protein receptor type II (BMPR2), which usually functions to stop vascular proliferation [7]. Therapies for PAH include pulmonary vasodilators like (epoprostenol, treprostinil, iloprost), guanylate cyclase (GSC) stimulators (Riociguat), and endothelin receptor antagonists (bosentan, macitentan, ambrisentan).